MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 74 filers reported holding MARINUS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,381,032 | -21.2% | 2,904,476 | +6.3% | 0.05% | -17.2% |
| Q2 2023 | $29,661,375 | +111.3% | 2,731,250 | +34.2% | 0.06% | +106.5% |
| Q1 2023 | $14,038,050 | +71.8% | 2,034,500 | -0.9% | 0.03% | +55.0% |
| Q4 2022 | $8,168,950 | -0.7% | 2,052,500 | +65.9% | 0.02% | 0.0% |
| Q3 2022 | $8,229,000 | +34.7% | 1,237,500 | -2.0% | 0.02% | +42.9% |
| Q2 2022 | $6,111,000 | -48.2% | 1,262,500 | 0.0% | 0.01% | -36.4% |
| Q1 2022 | $11,804,000 | -21.3% | 1,262,500 | 0.0% | 0.02% | -18.5% |
| Q4 2021 | $14,999,000 | +4.4% | 1,262,500 | 0.0% | 0.03% | -3.6% |
| Q3 2021 | $14,367,000 | -36.6% | 1,262,500 | 0.0% | 0.03% | -36.4% |
| Q2 2021 | $22,649,000 | +0.0% | 1,262,500 | -13.7% | 0.04% | -4.3% |
| Q1 2021 | $22,640,000 | +26.9% | 1,462,500 | 0.0% | 0.05% | +17.9% |
| Q4 2020 | $17,843,000 | -5.1% | 1,462,500 | 0.0% | 0.04% | -17.0% |
| Q3 2020 | $18,793,000 | – | 1,462,500 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |